Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 5:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Peripheral Neuropathy Clear all
Recruiting Phase 1 Interventional

B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

NCT04897321
View directory record Official record
Conditions
Pediatric Solid Tumor, Osteosarcoma, Rhabdomyosarcoma, Neuroblastoma, Ewing Sarcoma, Wilms Tumor, Adrenocortical Cancer, Desmoplastic Small Round Cell Tumor, Germ Cell Cancer, Rhabdoid Tumor, Clear Cell Sarcoma, Hepatoblastoma, Melanoma, Carcinoma, Malignant Peripheral Nerve Sheath Tumors, Soft Tissue Sarcoma
Interventions
Fludarabine, Cyclophosphamide, MESNA, B7-H3 CAR T cells
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Sep 9, 2026, 5:53 PM EDT
Terminated Phase 2 Interventional

To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP

NCT05581199
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyneuropathy
Interventions
Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly, Batoclimab 340 mg SC weekly, Placebo
Drug
Lead sponsor
Immunovant Sciences GmbH
Industry
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
21
States / cities
Scottsdale, Arizona • Los Angeles, California • Aurora, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 9, 2026, 5:53 PM EDT
Recruiting Not applicable Interventional

CEM-Plate and CEM-Cage First-In-Human Use Efficacy Study

NCT04883411
View directory record Official record
Conditions
Neck Pain, Spondylosis, Spondylosis With Myelopathy, Spondylosis With Radiculopathy, Spondylosis With Radiculopathy Cervical Region, Intervertebral Disc Disorder Cervical
Interventions
CEM-Plate Anterior Cervical Plating System and CEM-Cage Cervical Interbody System
Device
Lead sponsor
ReVivo Medical, Corp.
Industry
Eligibility
22 Years to 79 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
Union, New Jersey • Albany, New York • Williamsville, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2025 · Synced Sep 9, 2026, 5:53 PM EDT
Not listed Phase 2Phase 3 Interventional Accepts healthy volunteers

Fibrin for Chronic Multi-level Discogenic Low Back Pain

NCT04621799
View directory record Official record
Conditions
Low Back Pain, Disc Disease, Disc Degeneration, Radiculopathy, Annular Disc Tear
Interventions
Fibrin sealant
Drug
Lead sponsor
Pauza, Kevin, MD
Other
Eligibility
18 Years to 80 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Tyler, Texas
Source: ClinicalTrials.gov public record
Updated Nov 8, 2020 · Synced Sep 9, 2026, 5:53 PM EDT
Completed Phase 3 Interventional Results available

Extension of Phase 3 Gene Therapy for Painful Diabetic Neuropathy

NCT04055090
View directory record Official record
Conditions
Painful Diabetic Neuropathy, Diabetic Neuropathy, Painful
Interventions
Long-Term Follow-Up of Patients who Received Engensis (VM202), Long-Term Follow-Up of Patients who Received Placebo
Genetic · Drug
Lead sponsor
Helixmith Co., Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
14
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Sacramento, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Sep 9, 2026, 5:53 PM EDT
Completed Not applicable Interventional Results available

Dispersal Pattern for Spine Injections (Gadolinium Contrast)

NCT02217280
View directory record Official record
Conditions
Cervical Radiculopathy
Interventions
Injection with Gadolinium
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 27, 2017 · Synced Sep 9, 2026, 5:53 PM EDT
Completed Early Phase 1 Interventional

Spectrum of Peripheral and Autonomic Neuropathies in Patients With aTTRwt Amyloidosis and Response to Patisiran Therapy

NCT05023889
View directory record Official record
Conditions
Polyneuropathies, Wild Type ATTR Amyloidosis, Wild-Type Transthyretin-Related (ATTR)Amyloidosis, Wild-Type Transthyretin Cardiac Amyloidosis, Transthyretin Amyloidosis
Interventions
patisiran
Drug
Lead sponsor
Austin Neuromuscular Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 9, 2026, 5:53 PM EDT
Completed Phase 2 Interventional

A 12-Week Study of Topical Pirenzepine or Placebo in Type 2 Diabetic Patients (T2DM) With Painful Peripheral Neuropathy

NCT04786340
View directory record Official record
Conditions
Painful Diabetic Neuropathy, Diabetes Mellitus
Interventions
Active: WST-057 4mL (146 mg pirenzepine free base monohydrate) topical solution, Placebo: WST-057 4mL topical solution
Drug
Lead sponsor
WinSanTor, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 17, 2023 · Synced Sep 9, 2026, 5:53 PM EDT
Suspended Phase 2 Interventional

Vitamin D Supplementation on Reported Rates of Taxane-Induced Neuropathy

NCT05259527
View directory record Official record
Conditions
Neuropathic Pain
Interventions
Ergocalciferol Capsules, Cholecalciferol Capsules
Drug · Dietary Supplement
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 9, 2026, 5:53 PM EDT
Recruiting Early Phase 1 Interventional

Efficacy of a Topical Palmitated Formulation of Capsaicin (Capsadyn®) In the Treatment of Diabetic Neuropathic Foot Pain

NCT07260656
View directory record Official record
Conditions
Diabetic Neuropathies, Painful, Diabetic Foot, Diabetic Peripheral Neuropathy
Interventions
Capsaicin Palmitate, Placebo
Drug
Lead sponsor
Carilion Clinic
Other
Eligibility
25 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Sep 9, 2026, 5:53 PM EDT
Withdrawn Early Phase 1 Interventional

Phytocannabinoids for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors

NCT05672342
View directory record Official record
Conditions
Breast Carcinoma, Chemotherapy-Induced Peripheral Neuropathy, Colon Carcinoma
Interventions
Cannabidiol, Delta-8-Tetrahydrocannabinol, Placebo Administration, Questionnaire Administration
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 8, 2024 · Synced Sep 9, 2026, 5:53 PM EDT
Completed Phase 2 Interventional

Stem Cell Mobilization in Diabetic Neuropathy Subjects Receiving SB-509

NCT00665145
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Polyneuropathy
Interventions
SB-509, Placebo
Drug
Lead sponsor
Sangamo Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
La Jolla, California • Walnut Creek, California • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2012 · Synced Sep 9, 2026, 5:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Cost Information on Carpal Tunnel Syndrome Treatment Decisions

NCT03880812
View directory record Official record
Conditions
Carpal Tunnel Syndrome
Interventions
Societal cost
Other
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 89 Years
Enrollment
184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
6
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Sep 9, 2026, 5:53 PM EDT
Recruiting No phase listed Observational

Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors

NCT05868629
View directory record Official record
Conditions
Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors
Interventions
Non-investigational
Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Year to 100 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
8
States / cities
Torrance, California • Denver, Colorado • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Sep 9, 2026, 5:53 PM EDT
Completed No phase listed Observational

Natural History and Biology of Skin Neurofibromas in Neurofibromatosis Type 1

NCT00314119
View directory record Official record
Conditions
Neurofibromatosis Type 1, Neurofibroma
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
20 Years to 99 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 9, 2026, 5:53 PM EDT
Terminated Not applicable Interventional Results available

An Evaluation of the Effect of Low Level Laser Therapy on Diabetic Peripheral Neuropathy Pain

NCT04006392
View directory record Official record
Conditions
Diabetic Peripheral Neuropathy
Interventions
Erchonia FX-635, Placebo Laser
Device
Lead sponsor
Erchonia Corporation
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
4
States / cities
Mesa, Arizona • Costa Mesa, California • Hialeah, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2023 · Synced Sep 9, 2026, 5:53 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Treatment of Charcot-Marie-Tooth Disease, Axonal, Type 2S (CMT2S) in an Individual Patient

NCT07223632
View directory record Official record
Conditions
Charcot Marie Tooth Disease (CMT), Neuromuscular Diseases (NMD)
Interventions
VCA-894A
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 9, 2026, 5:53 PM EDT
Withdrawn Not applicable Interventional

Coordinated Reset Spinal Cord Stimulation

NCT04997278
View directory record Official record
Conditions
Pain, Neuropathic, Failed Back Surgery Syndrome
Interventions
Coordinated Reset spinal cord stimulation
Device
Lead sponsor
Stanford University
Other
Eligibility
22 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Sep 9, 2026, 5:53 PM EDT
Enrolling by invitation Phase 3 Interventional

Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP

NCT06859099
View directory record Official record
Conditions
Polyneuropathy, Inflammatory Demyelinating, Chronic
Interventions
Riliprubart Prefilled Pen (PFP)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
3
States / cities
Homewood, Alabama • Kansas City, Kansas • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 9, 2026, 5:53 PM EDT
Not yet recruiting Phase 1 Interventional

OER Glibenclamide for Neuropathic Pain in Multiple Sclerosis

NCT07221799
View directory record Official record
Conditions
Multiple Sclerosis, Neuropathic Pain
Interventions
glibenclamide, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Sep 9, 2026, 5:53 PM EDT
Completed Phase 1 Interventional

Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas

NCT00727233
View directory record Official record
Conditions
Neurofibromatosis Type I, Plexiform Neurofibroma
Interventions
Nexavar (BAY 43-9006) (Sorafenib), Toxicity, Pharmacokinetics, Pharmacodynamics, Radiographic Evaluation, QOL assessment, Neuropsychological, Bony Toxicity
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
3 Years to 18 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Birmingham, Alabama • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Sep 9, 2026, 5:53 PM EDT
Completed Phase 2 Interventional

Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy

NCT00406458
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Polyneuropathy
Interventions
SB-509, Normal Saline
Drug · Other
Lead sponsor
Sangamo Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
14
States / cities
La Jolla, California • Lakewood, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2012 · Synced Sep 9, 2026, 5:53 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Electrical Nerve Stimulation of the Ulnar Nerve

NCT02566616
View directory record Official record
Conditions
Cubital Tunnel Syndrome
Interventions
Ulnar Nerve Stimulation
Device
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Sep 9, 2026, 5:53 PM EDT
Recruiting No phase listed Observational

The KinematX Midcarpal Total Wrist Arthroplasty Registry

NCT05719935
View directory record Official record
Conditions
Scapholunate Advanced Collapse (SLAC), Scapholunate Crystalline Advanced Collapse (SCAC), Scaphoid, Trapezium, and Trapezoid Advanced Collapse (STTAC), Carpal Tunnel Syndrome (CTS), Kienbock's Disease of Adults, Radial Malunion, Ulnar Translocation, Post Traumatic Arthritis, Inflammatory Arthritis, Osteoarthritis, Scaphoid Non-union Advanced Collapse (SNAC)
Interventions
KinematX total wrist arthroplasty system
Device
Lead sponsor
Extremity Medical
Industry
Eligibility
18 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2035
U.S. locations
4
States / cities
Loma Linda, California • Tampa, Florida • Indianapolis, Indiana + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Sep 9, 2026, 5:53 PM EDT